As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Protein binding: plasma, brain tissue, microsomal protein, FBS; Erythrocyte /plasma partition ratio
Optimization permeability and transport: Caco - 2. MDCK - MDR1 / BCRP, OATs/OCTs/OATPs
In vitro metabolic DDI: P450 inhibited TDI, P450 induced /PXR, metabolic enzyme phenotype.
Metabolic stability: microsomes, S9, hepatocytes, plasma, whole blood
Metabolite Screening and Identification: in vitro, in vivo, and GSH Trapping
In vivo PK: rat, mouse, dog, monkey, pig, rabbit box/single administration
Routes of administration: IV/IJVC/SC/TD/IM/IP/PO/SL/IN/IVT
Continuous cross/single point blood sampling
BBB(homogenate /CSF), Tissue distribution excretion (BDC), in vivo DDI (ABT)